Altered fractionation schedules in radiation treatment: a review.

Conventionally fractionated radiotherapy is delivered in 1.8- to 2.0-Gy fractions. With increases in understanding of radiation and tumor biology, various alterations of radiotherapy schedules have been tested in clinical trials and are now regarded by some as standard treatment options. Hyperfractionation is delivered through a greater number of smaller treatment doses. Accelerated fractionation decreases the amount of time over which radiotherapy is delivered typically by increasing the number of treatments per day. Hypofractionation decreases the number of fractions delivered by increasing daily treatment doses. Furthermore, many of these schedules have been tested with concurrent chemotherapy regimens. In this review, we summarize the major clinical studies that have been conducted on altered fractionation in various disease sites.

[1]  venlig hilsen,et al.  Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck : DAHANCA 6 and 7 randomised controlled trial , 2016 .

[2]  Geoffrey G. Zhang,et al.  Clinical Investigation : Thoracic Cancer Study of 201 Non-Small Cell Lung Cancer Patients Given Stereotactic Ablative Radiation Therapy Shows Local Control Dependence on Dose Calculation Algorithm , 2022 .

[3]  T. Iuchi,et al.  Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. , 2014, International journal of radiation oncology, biology, physics.

[4]  M. Steinberg,et al.  Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. , 2013, International journal of radiation oncology, biology, physics.

[5]  R. Stoyanova,et al.  Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Anurag K. Singh,et al.  Radiation Therapy Oncology Group (RTOG) Protocol 0915: A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer , 2013 .

[7]  Joanne S Haviland,et al.  The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. , 2013, The Lancet. Oncology.

[8]  Ravi Shridhar,et al.  Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. , 2013, International journal of radiation oncology, biology, physics.

[9]  M. Santoro,et al.  Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years , 2013, Radiation oncology.

[10]  Wei Xu,et al.  Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Christopher U. Jones,et al.  RTOG 90-03: Final Report , 2012 .

[12]  Allen Waziri,et al.  Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. , 2012, International journal of radiation oncology, biology, physics.

[13]  Didier Frappaz,et al.  Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[14]  R. Fisher,et al.  Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. , 2012, The Lancet. Oncology.

[15]  Suresh Senan,et al.  Curative treatment of Stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. , 2012, International journal of radiation oncology, biology, physics.

[16]  V. Grégoire,et al.  Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. , 2012, The Lancet. Oncology.

[17]  K. Horst,et al.  Fractionation for whole breast irradiation: An American Society for Radiation Oncology (ASTRO) evidence-based guideline , 2012 .

[18]  J. Stockman Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer , 2012 .

[19]  W. Hohenberger,et al.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Senan,et al.  Outcomes of Stereotactic Ablative Radiotherapy for Centrally Located Early-Stage Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  J. Fowler,et al.  Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. , 2011, International journal of radiation oncology, biology, physics.

[22]  E. Kasper,et al.  Stereotactic body radiotherapy reirradiation for recurrent epidural spinal metastases. , 2011, International journal of radiation oncology, biology, physics.

[23]  Benjamin Movsas,et al.  Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. , 2011, Journal of the National Cancer Institute.

[24]  L. Specht,et al.  The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  V. Budach,et al.  Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  Hein Putter,et al.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. , 2011, The Lancet. Oncology.

[27]  D. Kuban,et al.  Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? , 2008, International journal of radiation oncology, biology, physics.

[28]  M. Gapany Mature results of a randomized trial of accelerated hyperfractionated versus conventional radiotherapy in head-and-neck cancer , 2011 .

[29]  K. Ang,et al.  Hyperfractionated or accelerated radiotherapy for head and neck cancer. , 2010 .

[30]  N. Neerchal,et al.  Image-Guided Stereotactic Radiosurgery for Locally Advanced Pancreatic Adenocarcinoma Results of First 85 Patients , 2010, Journal of Gastrointestinal Surgery.

[31]  C. Grau,et al.  Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial. , 2010, The Lancet. Oncology.

[32]  R. Weber,et al.  A Phase III Trial to Test Accelerated Versus Standard Fractionation in Combination with Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Report of Efficacy and Toxicity , 2010 .

[33]  Anthony Fyles,et al.  Long-term results of hypofractionated radiation therapy for breast cancer. , 2010, The New England journal of medicine.

[34]  Andrea Bezjak,et al.  Stereotactic body radiation therapy for inoperable early stage lung cancer. , 2010, JAMA.

[35]  D. Heron,et al.  Fractionated Stereotactic Body Radiation Therapy in the Treatment of Previously-Irradiated Recurrent Head and Neck Carcinoma: Updated Report of the University of Pittsburgh Experience , 2009, American journal of clinical oncology.

[36]  Tarek Mekhail,et al.  A Comparison of Two Stereotactic Body Radiation Fractionation Schedules for Medically Inoperable Stage I Non-small Cell Lung Cancer: The Cleveland Clinic Experience , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[37]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[38]  R. Arriagada,et al.  Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. , 2009, The Lancet. Oncology.

[39]  A. Zietman,et al.  Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. , 2009, Urology.

[40]  Yun Yen,et al.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[41]  Jeffrey E. Lee,et al.  Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. , 2009, International journal of radiation oncology, biology, physics.

[42]  J. Monson,et al.  Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial , 2009, The Lancet.

[43]  M. Celeste Simon,et al.  The impact of O2 availability on human cancer , 2008, Nature Reviews Cancer.

[44]  J. Yarnold,et al.  The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial , 2008, The Lancet. Oncology.

[45]  J R Yarnold,et al.  The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial , 2008, The Lancet.

[46]  E. Glatstein,et al.  Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer , 2008 .

[47]  P. Warde,et al.  Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[48]  M. Parmar,et al.  Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. , 2007, The Lancet. Oncology.

[49]  W. Mendenhall,et al.  Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. , 2006, International journal of radiation oncology, biology, physics.

[50]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[51]  J. Bourhis,et al.  Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  Joos V Lebesque,et al.  Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  H. Yamazaki,et al.  Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. , 2006, International journal of radiation oncology, biology, physics.

[54]  A. Lippold,et al.  Soft x-ray therapy for cutaneous basal cell and squamous cell carcinomas. , 2005, Journal of the American Academy of Dermatology.

[55]  Sharon A. Spencer,et al.  Long Term Outcomes of RTOG 90–03: A Comparison of Hyperfractionation and Two Variants of Accelerated Fractionation to Standard Fractionation Radiotherapy for Head and Neck Squamous Cell Carcinoma , 2005 .

[56]  D. Brizel,et al.  Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[57]  Daniel W. Miller,et al.  Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. , 2005, JAMA.

[58]  L. Påhlman,et al.  Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  P. Wust,et al.  Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  W. J. Morris,et al.  Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  K. Rufibach,et al.  Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  Rainer Fietkau,et al.  Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.

[63]  T. Pawlik,et al.  Role of cell cycle in mediating sensitivity to radiotherapy. , 2004, International journal of radiation oncology, biology, physics.

[64]  E. Bruera,et al.  Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  Stephanie Frost,et al.  Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. , 2003, Chest.

[66]  John D. Roberts,et al.  RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. , 2003, International journal of radiation oncology, biology, physics.

[67]  Cai Grau,et al.  Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial , 2003, The Lancet.

[68]  G. Noël,et al.  Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomized German trial in advanced head-and-neck cancer , 2002 .

[69]  D. Hedley,et al.  Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  A. Serafin,et al.  A multicentre randomized/controlled trial of a conventional versus modestly accelerated radiotherapy in the laryngeal cancer: influence of a 1 week shortening overall time. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[71]  Rieken,et al.  [Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer]. , 2001, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[72]  J. Meza,et al.  Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG. , 2001, International journal of radiation oncology, biology, physics.

[73]  L. Peters,et al.  A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study , 2001 .

[74]  B. Jeremic,et al.  Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  W. Curran,et al.  Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. , 2001, Chest.

[76]  J. Naude,et al.  Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[77]  W. Curran,et al.  Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer : Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group , 2000 .

[78]  W. Mendenhall,et al.  Radiotherapy alone for clinical T4 skin carcinoma of the head and neck with surgery reserved for salvage , 2000 .

[79]  A Harvey,et al.  Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[80]  D. Joseph,et al.  A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[81]  R. Komaki,et al.  Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. , 1999, The New England journal of medicine.

[82]  Jay S. Cooper,et al.  A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003 , 1999 .

[83]  A. Huang,et al.  Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. , 1998, The New England journal of medicine.

[84]  A. Aupérin,et al.  Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. , 1997, British Journal of Cancer.

[85]  T. Walsh,et al.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. , 1996, The New England journal of medicine.

[86]  D. Nelson,et al.  Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas: Radiation therapy oncology group study 83‐02 , 1996, Cancer.

[87]  I. Näslund,et al.  Hyperfractionated radiotherapy of bladder cancer. A ten-year follow-up of a randomized clinical trial. , 1994, Acta oncologica.

[88]  K. Stelzer,et al.  A randomized prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma. , 1993, International journal of radiation oncology, biology, physics.

[89]  S Schraub,et al.  Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[90]  J. Cooper,et al.  Fraction size in external beam radiation therapy in the treatment of melanoma. , 1991, International journal of radiation oncology, biology, physics.

[91]  L. Souhami,et al.  Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. , 1991, International journal of radiation oncology, biology, physics.

[92]  C. Perez,et al.  External irradiation of epithelial skin cancer. , 1990, International journal of radiation oncology, biology, physics.

[93]  J. Lozier,et al.  Radiation therapy of skin carcinomas: results of a hypofractionated irradiation schedule in 675 cases followed more than 2 years. , 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[94]  B. Nilsson,et al.  Irradiation therapy with multiple small fractions per day in urinary bladder cancer. , 1985, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[95]  T. Kinsella,et al.  In vitro radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphological variants. , 1983, Cancer research.

[96]  R. Hatlevoll,et al.  Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the scandinavian glioblastoma study group , 1981, Cancer.

[97]  E. Alexander,et al.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.

[98]  H. Withers,et al.  Four R's of radiotherapy , 1975 .

[99]  R. Lindberg,et al.  Radiation therapy administered under conditions of tourniquet-induced local tissue hypoxia. , 1968, The American journal of roentgenology, radium therapy, and nuclear medicine.